Korean ADNI (K-ADNI) is working to comply with international standards of world-wide ADNI for development of new drugs for Alzheimer's Disease dementia patients; to evaluate the effects of vascular risk factors on Alzheimer's disease progression and Subcortical Vascular Dementia (SVaD), which comprises relatively large proportion of Asian dementia patients; and to establish the efficacy approval system for new dementia drugs. They are recruiting and collecting data comparable to that gathered through other WW-ADNI centers and data collected throughout this study are available to the research community. Recently, Korea ADNI was approved for government funding.
Alzheimer's Association National Office 225 N. Michigan Ave., Fl. 17, Chicago, IL 60601
Alzheimer's Association is a not-for-profit 501(c)(3) organization.
